Institut Pasteur Korea (IPK) and ST Pharm announced an anti-influenza Drug Discovery project. This joint research project aims to discover novel influenza virus entry inhibitors with the potential to prevent or control the spread of influenza by blocking the initial entry step of viral life cycle. 
The collaboration between ST Pharm and IPK is supported by the Gyeonggi Provincial Government and it will take place over the next three years from Oct 2016. 
The collaboration combines IPK’s basic science research capabilities and cell-based screening technology with ST Pharm‘s virtual Open Innovative Virtual (OIV) R&D strategy.


Source: Digital Times (September 27, 2016)